2Papaevangelu G,Roumeliotou-Karayannis A,Vissoulis C,et al.Immunogenicity of a five-microgram dose of hepatitis B vaccine[J].J Med Viral 1985,15(1):65-69.
3Duval B,Boulianne N,De Serres G,et al.Comparative immunogenicity under field conditions of recombinant hepatitis B vaccines in 8-10-year-old children[J].Vaccine 2000,14:18(15):1467-1472.
4Goldfarb J,Medendrop SV,Garcia H,et al.Comparison study of the immnuogenicity and safety of and 10-microgram dosages of a recombinant hepatitis B vaccine in healthy infants[J].Pediatr Infect Dis J 1996,15(9):764-767.
5Greenberg DP,Vadheim CM,Wong VK,et al.Comparative study and immnuogenicity of two recombinant hepatitis B given to infants at two,four and six months of age[J].Pediatr Infect Dis J 1996,(1579):590-596.
6West DJ,Snavely DB,Zajac BA,et al.Development and persistence of antibody in a high risk institutionalized population given plasma-derived hepatitis B vaccine[J].Vaccine 1990,8(2):111-114.
7Van Herk K,Van Damme.P,Thoelen S,et al.Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine:8-year results[J].Vaccine 1998,16(20):1933-1935.
8Goh KT,Tan KL,Kong KH,et al.Comparison of a immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children:a four-year follow-up study[J].Bull world health Organm 1992,70(2):233-239.
9Ostrow DH,Edwards B,Kimes D,et al.Quantitation of hepatitis B surface antibody by an automated micropartical enzyme immunoassay[J].J Viral Methods 1991,32(2-3):265-276.
10Davis R L,Black S,Shinefield H.Post-marketing evaluation of the short term safety of COMVAX[J].Vaccine 2004,22(3-4):536-543.
